Last Updated: November 16, 2026

Ethicon, Inc. Company Profile

« Back to Dashboard


Biologic Drugs for Ethicon, Inc.

Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,189,410 2015-06-07 DrugPatentWatch analysis and company disclosures
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,196,054 2015-06-07 DrugPatentWatch analysis and company disclosures
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,189,410 2015-06-07 DrugPatentWatch analysis and company disclosures
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,196,054 2015-06-07 DrugPatentWatch analysis and company disclosures
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,189,410 2015-06-07 DrugPatentWatch analysis and company disclosures
Ethicon, Inc. EVARREST fibrin sealant patch Patch 125392 7,196,054 2015-06-07 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

Ethicon Competitive Landscape Analysis: Market Position, Strengths and Strategic Insights

Last updated: September 26, 2026

Ethicon is a leading global surgical-device franchise within Johnson & Johnson MedTech, with strong positions in advanced wound closure, energy devices, stapling, surgical sealants, hemostats, and minimally invasive surgery. Its main competitive advantages are hospital relationships, procedural breadth, clinical evidence, global distribution, and integration with Johnson & Johnson’s broader medical-device platform.

Ethicon faces its strongest competition from Medtronic, Intuitive Surgical, Olympus, Stryker, Teleflex, Baxter, B. Braun, Applied Medical, and emerging robotic-surgery companies. Its principal strategic risks are hospital purchasing pressure, procedure migration toward robotic platforms, lower-cost competitors, technology substitution, and the loss of differentiation in mature categories.

Ethicon’s standalone revenue, patent portfolio, and product-level margins are not publicly disclosed because Johnson & Johnson reports MedTech results at a broader segment level. Johnson & Johnson’s MedTech sales were approximately $30.4 billion in 2023 and approximately $30.8 billion in 2024, but Ethicon’s contribution cannot be isolated from public reporting. [1, 2]

What is Ethicon’s market position in surgical devices?

Ethicon is one of the largest branded suppliers of surgical products worldwide. The company sells products across open surgery, laparoscopic surgery, bariatric surgery, thoracic surgery, colorectal surgery, gynecology, urology, and general surgery.

Its market position is strongest where products are purchased as part of a broader procedural system rather than as individual commodities.

Segment Representative Ethicon products or brands Main competitors
Surgical stapling ECHELON, ECHELON FLEX, powered stapling systems Medtronic, Intuitive Surgical, Covidien legacy products, Olympus, Applied Medical
Energy devices HARMONIC, ENSEAL Medtronic LigaSure, Olympus, Erbe, Stryker
Sutures and wound closure ETHICON sutures, STRATAFIX, DERMABOND Medtronic, Teleflex, Stryker, B. Braun, Peters Surgical
Hemostasis SURGIFLO, EVARREST, ETHICON topical hemostats Baxter, BD, Integra LifeSciences, Pfizer legacy products
Surgical sealants VISTASEAL and other adjunctive products Baxter, CryoLife, Integra, B. Braun
Hernia and soft-tissue repair PROCEED and related products Medtronic, Bard/Davol, Gore, Atrium, B. Braun
Minimally invasive surgery Trocar, access, closure, and procedural tools Applied Medical, Medtronic, Olympus, Stryker

Ethicon’s strategic value comes from its ability to sell multiple products into the same operating room, hospital system, and surgical specialty. A hospital that standardizes on Ethicon stapling may also evaluate Ethicon energy, closure, hemostasis, and wound-sealing products.

How does Ethicon compare with Medtronic, Intuitive Surgical, and Stryker?

Ethicon competes against different companies depending on the procedure and product category. No single competitor matches Ethicon across every product line.

Ethicon versus Medtronic

Medtronic is Ethicon’s broadest direct competitor. The companies compete in surgical stapling, energy devices, wound closure, hernia repair, and minimally invasive surgery.

Medtronic’s strengths include:

  • The LigaSure energy franchise.
  • The Endo GIA and related stapling portfolio.
  • Large hospital-account coverage.
  • A broad surgical and cardiovascular device base.
  • Global distribution and established contracting relationships.

Ethicon’s counterposition is its combination of ECHELON stapling, HARMONIC and ENSEAL energy, sutures, wound closure, hemostasis, and Johnson & Johnson commercial scale.

Ethicon versus Intuitive Surgical

Intuitive Surgical is primarily a robotic-surgery platform company, while Ethicon is primarily a surgical consumables and instruments company. The competitive relationship is indirect in some areas and direct in others.

Intuitive has a stronger position in:

  • Robotic capital equipment.
  • Robotic instruments.
  • Procedure-specific robotic ecosystems.
  • Recurring instrument and accessory revenue.
  • Clinical and training infrastructure around robotic surgery.

Ethicon has greater breadth in conventional open and laparoscopic surgery and does not depend on a single robotic platform. Its main strategic challenge is that robotic procedures can shift instrument purchasing, surgeon preference, and hospital capital budgets away from conventional laparoscopic equipment.

Ethicon versus Stryker

Stryker competes with Ethicon in surgical equipment, operating-room systems, instruments, and selected procedural products. Stryker has a stronger position in orthopedics, neurotechnology, operating-room equipment, and surgical visualization.

Ethicon has greater depth in soft-tissue surgery, closure, stapling, energy, and hemostasis. Stryker’s advantage is its ability to link surgical products with hospital capital equipment, imaging, navigation, and orthopedic procedure platforms.

Ethicon versus Applied Medical and Olympus

Applied Medical competes aggressively in laparoscopic instruments, trocars, access devices, and procedure-specific products. Its lower-cost positioning can pressure Ethicon in value-oriented hospital systems.

Olympus has substantial strength in endoscopy, visualization, and therapeutic procedures. The company competes with Ethicon where minimally invasive instruments and endoscopic procedures overlap.

What are Ethicon’s strongest competitive advantages?

What role does the Johnson & Johnson platform play?

Johnson & Johnson gives Ethicon access to:

  • Global regulatory and market infrastructure.
  • Large hospital-account relationships.
  • Medical education and surgeon training.
  • Supply-chain scale.
  • Clinical research resources.
  • Corporate capital for acquisitions and product development.
  • Cross-selling across MedTech specialties.

This platform is difficult for smaller device companies to replicate. It also gives Ethicon negotiating leverage in multispecialty hospital contracts.

How strong is Ethicon’s product portfolio?

Ethicon has one of the broadest portfolios in general surgery. Its products are integrated into recurring procedures, which creates repeat demand even when hospitals defer capital spending.

Consumable and procedure-linked products offer several commercial benefits:

  1. Purchases recur with each procedure.
  2. Switching requires surgeon training and workflow changes.
  3. Clinical familiarity can support brand retention.
  4. Products can be bundled into account-level contracts.
  5. New products can be introduced through existing distribution channels.

The main limitation is that many surgical products are mature and face price competition. Brand strength does not eliminate hospital pressure to reduce unit costs.

Does Ethicon have clinical and workflow differentiation?

Ethicon has invested in clinical evidence for stapling, energy, hemostasis, and wound closure. In surgical devices, differentiation often depends on workflow outcomes rather than a single active ingredient. Relevant purchasing factors include:

  • Reliability during tissue transection.
  • Seal strength.
  • Bleeding control.
  • Ease of use.
  • Reduced instrument exchanges.
  • Operative time.
  • Complication rates.
  • Compatibility with established surgical technique.

Products that demonstrate measurable procedural benefits have stronger protection against commoditization than products differentiated mainly by branding.

What patents and intellectual property protect Ethicon products?

Ethicon’s intellectual-property protection is product-specific and distributed across patents, trademarks, trade secrets, regulatory clearances, clinical data, manufacturing know-how, and surgeon training.

Unlike branded pharmaceuticals, most Ethicon products are not protected through the FDA Orange Book. The Orange Book primarily lists approved drug products and patents submitted for those products. Surgical staplers, energy devices, sutures, hemostats, and trocars typically rely on device patents, trademarks, regulatory submissions, and trade-secret protection instead. [3]

What types of IP are most important?

Ethicon’s relevant IP categories include:

  • Staple geometry and staple-cartridge design.
  • Anvil and jaw mechanisms.
  • Powered actuation systems.
  • Tissue compression and sensing.
  • Ultrasonic blade design.
  • Bipolar vessel-sealing technology.
  • Suture coatings and barbed-suture structures.
  • Adhesive formulations.
  • Hemostatic matrices and delivery systems.
  • Packaging, sterilization, and manufacturing processes.
  • Procedure-specific instruments and ergonomic designs.

Ethicon’s most valuable commercial protection may come from the combination of patent rights and operational barriers. Hospitals often require validated products, surgeon acceptance, supply reliability, and training before switching vendors.

When do Ethicon patents expire?

There is no single Ethicon patent-expiration date. Each product family may include patents with different filing dates, continuations, design patents, foreign counterparts, and terminal disclaimers. Public patent databases identify individual rights, but Johnson & Johnson does not publish a consolidated expiration schedule for the Ethicon portfolio.

Patent expiration creates greater risk in standardized mechanical products than in products supported by manufacturing complexity, clinical evidence, or integrated workflows. A competitor may legally enter after expiration but still face hospital qualification and surgeon-adoption barriers.

What is the FDA regulatory status of Ethicon products?

Ethicon products are regulated primarily as medical devices, biologics, or combination products depending on their composition and intended use.

Which FDA pathways apply?

Common regulatory pathways include:

  • 510(k) clearance for devices substantially equivalent to a legally marketed predicate.
  • Premarket approval for higher-risk devices requiring clinical evidence.
  • De novo classification for certain novel moderate-risk devices.
  • Biologics licensing or related biologic requirements for some blood-derived or biologic surgical products.
  • Supplemental submissions for design or indication changes.
  • Establishment registration and device listing.
  • Quality-system and postmarket reporting requirements.

FDA’s 510(k) database and device registration systems provide product-level regulatory records. [4] Regulatory clearance is not the same as market exclusivity. A cleared device may face competition from other cleared products using the same or a similar predicate.

Are biosimilar risks relevant to Ethicon?

Traditional biosimilar risk is not central to Ethicon because most of its portfolio consists of devices rather than therapeutic biologics. Biosimilar competition does not apply to sutures, staplers, energy instruments, trocars, or most mechanical surgical products.

Biologic and plasma-derived surgical adjuncts can face a different competitive framework involving biologic regulation, manufacturing controls, clinical evidence, and product quality. Those products should be assessed separately from Ethicon’s conventional device portfolio.

Which companies are challenging Ethicon commercially?

Ethicon’s competitive threats differ by market.

Competitor Primary challenge
Medtronic Broad direct competition in stapling, energy, and minimally invasive surgery
Intuitive Surgical Robotic procedure migration and platform-driven instrument demand
Stryker Operating-room integration, visualization, and hospital capital relationships
Applied Medical Value pricing in laparoscopic access and instruments
Olympus Endoscopic visualization and minimally invasive procedural tools
Teleflex Closure, vascular access, and specialty procedural products
Baxter Hemostasis, sealants, and surgical adjuncts
B. Braun Global value competition and broad surgical distribution
Integra LifeSciences Wound care, hemostasis, and reconstructive surgery
Gore Hernia repair, soft-tissue implants, and specialty surgical materials

Private-label and regional manufacturers create additional pressure in sutures, laparoscopic instruments, trocars, and basic closure products. Hospitals increasingly use group purchasing organizations and integrated delivery networks to negotiate price reductions.

What generic-entry and substitution risks exist for Ethicon?

The term “generic entry” is less precise for devices than for pharmaceuticals. Competitors generally enter through their own FDA clearance, predicate-based submissions, or new product approvals rather than an abbreviated generic-drug pathway.

The principal entry risks are:

  • Competitor clearance of substantially equivalent devices.
  • Patent expiration or invalidation.
  • Design-arounds that avoid asserted claims.
  • Hospital conversion to lower-cost products.
  • Robotic substitution.
  • Procedure decline or migration.
  • Surgeon preference changes.
  • Product recalls or adverse-event publicity.
  • Supply interruptions.
  • Contract losses to group purchasing organizations.

The highest substitution risk is likely in mature laparoscopic instruments, trocars, basic sutures, and commoditized closure products. The risk is lower where products require specialized manufacturing, clinical validation, surgeon training, or integrated procedural workflows.

What patent litigation and settlement risks affect Ethicon?

Ethicon and Johnson & Johnson have historically participated in device and medical-product patent disputes, but there is no pharmaceutical-style Paragraph IV litigation framework for most Ethicon products. Paragraph IV certifications apply to abbreviated new drug applications, not ordinary medical-device clearances.

Relevant litigation categories include:

  • Patent infringement over stapling mechanisms.
  • Disputes involving energy devices.
  • Trade-secret claims involving device engineering or manufacturing.
  • Product-liability litigation.
  • False-marking and advertising disputes.
  • Antitrust allegations involving contracting or bundling.
  • Patent-validity challenges before the Patent Trial and Appeal Board.
  • International infringement actions.

A complete product-level litigation assessment requires mapping each active product family to asserted patents, court dockets, PTAB proceedings, and settlement terms. Ethicon’s public corporate reporting does not provide a single consolidated litigation schedule for every product.

What licensing deals and partnerships support Ethicon?

Ethicon’s commercial strategy has included internal development, acquisitions, licensing, and partnerships across surgical technology. Johnson & Johnson has used acquisitions to expand in robotic surgery, digital surgery, advanced instrumentation, and procedural technologies.

The company’s most important strategic development areas include:

  • Robotic-assisted surgery.
  • Digital surgery and data integration.
  • Advanced stapling.
  • Tissue sensing.
  • Energy-based vessel sealing.
  • Hemostasis and surgical sealants.
  • Minimally invasive access.
  • Procedure-specific platforms.

Johnson & Johnson’s acquisition of Auris Health expanded its presence in robotic-assisted surgery and supported the development of the OTTAVA surgical robotic system. Johnson & Johnson disclosed that the OTTAVA program remained under development and was not equivalent to an FDA-cleared commercial robotic platform during the company’s reported development period. [1, 5]

Partnership risk is material in robotics because platform adoption depends on installed-base growth, surgeon training, hospital capital budgets, software development, and regulatory execution.

How exposed is Johnson & Johnson revenue to Ethicon?

Ethicon’s exact revenue exposure is not publicly reported. Johnson & Johnson reports MedTech revenue by broader franchise categories and geographic markets rather than by every operating company or brand.

This limits outside analysis in four areas:

  • Ethicon’s standalone growth rate.
  • Product-level operating margins.
  • Revenue at risk from patent expiration.
  • The financial effect of a specific competitor or product recall.

MedTech is strategically important to Johnson & Johnson, but Ethicon-specific valuation requires internal management reporting or a product-level market model. Public investors can assess the franchise through Johnson & Johnson’s MedTech results, procedure volumes, organic growth, acquisitions, and segment margins, but cannot directly reconcile Ethicon sales.

What is Ethicon’s competitive outlook through 2030?

Ethicon’s market position should remain strong in core general surgery, but growth will depend on moving from individual instruments toward procedural platforms.

The most important growth opportunities are:

  • Robotic-assisted surgery.
  • Advanced stapling and tissue management.
  • Surgical visualization and digital workflow.
  • Hemostasis and blood-loss reduction.
  • Ambulatory and outpatient procedures.
  • Emerging-market surgical access.
  • Procedure-specific integrated solutions.

The principal risks are:

  • Medtronic’s direct competitive scale.
  • Intuitive’s robotic installed base.
  • Lower-cost laparoscopic competitors.
  • Hospital purchasing consolidation.
  • Product commoditization.
  • Regulatory delays in new platforms.
  • Litigation involving device performance or intellectual property.
  • Weak procedure volumes caused by reimbursement or staffing constraints.

Ethicon’s strategic priority is to defend its high-volume consumables while building a stronger position in connected and robotic surgery. Its ability to combine instruments, consumables, software, clinical data, and training will determine whether it retains influence as surgery becomes more platform-based.

Key Takeaways

  • Ethicon is a leading surgical-device franchise within Johnson & Johnson MedTech.
  • Its strongest categories are stapling, energy, sutures, wound closure, hemostasis, and surgical adjuncts.
  • Medtronic is the closest broad-based competitor.
  • Intuitive Surgical creates the largest platform-level threat through robotic procedure migration.
  • Ethicon’s standalone revenue and margins are not publicly disclosed.
  • Device patents, regulatory clearances, trademarks, manufacturing know-how, and surgeon adoption provide the main barriers to entry.
  • Orange Book and Paragraph IV analysis generally do not apply to Ethicon’s conventional device portfolio.
  • The highest commoditization risk is in mature laparoscopic instruments, trocars, basic sutures, and closure products.
  • Ethicon’s future competitive position depends on robotics, digital surgery, advanced stapling, and integrated procedural workflows.
  • Johnson & Johnson’s corporate scale remains a major advantage, but hospital price pressure limits the ability to rely on brand strength alone.

FAQs About Ethicon’s Competitive Landscape

Is Ethicon owned by Johnson & Johnson?

Yes. Ethicon is part of Johnson & Johnson MedTech, the company’s medical-device business.

Who is Ethicon’s biggest competitor?

Medtronic is generally Ethicon’s broadest direct competitor across stapling, energy devices, and minimally invasive surgery. Intuitive Surgical is the strongest platform competitor in robotic-assisted surgery.

Does Ethicon have pharmaceutical-style exclusivity?

Usually not. Ethicon products are primarily medical devices and rely on device patents, FDA clearances, trademarks, clinical evidence, manufacturing controls, and hospital adoption rather than pharmaceutical exclusivity periods.

Are Ethicon products listed in the FDA Orange Book?

Most conventional Ethicon surgical devices are not Orange Book products. The Orange Book is principally relevant to approved drug products and associated drug patent listings.

What is Ethicon’s biggest strategic risk?

The largest strategic risk is the shift from standalone surgical instruments toward robotic, digitally integrated, and platform-based procedures. Ethicon must preserve its consumables franchise while establishing a stronger position in those platforms.

References

  1. Johnson & Johnson. (2024). 2023 annual report. https://www.jnj.com
  2. Johnson & Johnson. (2025). 2024 annual report. https://www.jnj.com
  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
  4. U.S. Food and Drug Administration. (2024). 510(k) premarket notification database. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
  5. Johnson & Johnson. (2024). OTTAVA robotic surgical system program and Johnson & Johnson MedTech updates. https://www.jnj.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.